ArticleLife (Basel, Switzerland)2022
Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction.
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Effect of glucocorticoids on smell sensation in patients with non-traumatic olfactory disorders: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review.Current allergy and asthma reports · 2024Pooled it
- Article
- Granulocyte Colony Stimulating Factor (G-CSF) and Olfactory Function-A Clinical Pilot Study.Laryngoscope investigative otolaryngology · 2025Article
- Different Modalities in the Management of Post-COVID-19 Olfactory Dysfunction.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Long-term olfactory loss post-COVID-19: Pathobiology and potential therapeutic strategies.World journal of otorhinolaryngology - head and neck surgery · 2024Review
- Article
- Review
- Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies.Biomedicines · 2023Review
- The use of prescription drugs and health care services during the 6-month post-COVID-19 period.Scientific reports · 2023Article
- Olfactory Function and Olfactory Disorders.Laryngo- rhino- otologie · 2023Article
- Olfactory Dysfunction: Etiology, Diagnosis, and Treatment.Deutsches Arzteblatt international · 2023Review
- Therapies for COVID-19-Related Persistent Olfactory Disorders: One of the Good Fruits of the Pandemic.Pathogens (Basel, Switzerland) · 2023Article
- The Trajectories of Olfactory Dysfunction from the First to the Omicron Wave: Are We Getting over it?Pathogens (Basel, Switzerland) · 2022Article
- Post-Viral Olfactory Loss: What We Learned from the SARS-CoV-2 Pandemic.Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysically assessed the effect of intranasally applied mometasone furoate on the recovery of olfaction. The spray was applied with a long applicator so that the olfactory cleft could be reached effectively. After olfactory dysfunction had been confirmed psychophysically using Sniffin' Sticks, patients were randomly assigned to two different treatment arms: the study group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.